Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: A new standard in patient care?

Clinical and Translational Oncology

Volumn 9, Issue 7, 2007, Pages 409-411

  Gonzalez Martin A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADVANCED CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CATHETER COMPLICATION; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG WITHDRAWAL; EDITORIAL; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE OBSTRUCTION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PATIENT CARE; PATIENT COMPLIANCE; QUALITY OF LIFE; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; CARCINOMA; FEMALE; INDWELLING CATHETER; INFUSION; OVARY TUMOR; STANDARD;

ANTINEOPLASTIC AGENTS; CARCINOMA; CATHETERS, INDWELLING; FEMALE; HUMANS; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS; PATIENT CARE;

EID: 35748978846     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0077-5     Document Type: Editorial

References (19)

1. Jemal A, Siegel R, Ward E et al (2006) Cancer Statistics, 2006. CA Cancer J Clin 56:106-130
2. Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: A meta-analysis. J Clin Oncol 20:1248-1259
3. McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6
4. Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708
5. Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200
6. du Bois A, Lück H-J, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1330
7. du Bois A, Quinn M, Thigpen T et al (2005) 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16:vIii7-12
8. Dedrick RL, Myers CE, Bungay PM et al (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1-9
9. Casper ES, Kelsen DP, Alcock NW et al (1983) IP cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the ivroute. Cancer Treat Rep 67:235-238
10. Francis P, Rowinsky E, Schneider J et al (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study. J Clin Oncol 13:2961-2967
11. Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955
12. Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007
13. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43
14. (2006) Clinical advisory: NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer. Available on WWW at www.nlm.nih.gov/databases/alerts/ovarian_ip_chemo.html
15. Markman M, Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J Clin Oncol 24:988-993
16. Wenzel LB, Huang HQ, Armstrong DK et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:437-443
17. Walker JL, Armstrong DK, Huang HQ et al (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100:27-32
18. Ozols RF, Bookman MA, Young RC et al (2006) Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103:1-6
19. Gore M, du Bois A, Vergote I (2006) Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 24:4528-4530